People: Johns Hopkins Oncology Center Names Director, Plans Construction of New Facility

The Johns Hopkins School of Medicine's Oncology Center in Baltimore has named oncology professor Martin D. Abeloff as its new director. Currently, the university is planning the construction of a new building for the facility. The Oncology Center was created under the National Cancer Act of 1976. Along with an 84-bed hospital, the center has research programs in nearly every type of cancer, including breast, lung, colon, prostate, brain, and ovarian cancer, as well as leukemia. Abeloff had bee

Written byRon Kaufman
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Oncology Center was created under the National Cancer Act of 1976. Along with an 84-bed hospital, the center has research programs in nearly every type of cancer, including breast, lung, colon, prostate, brain, and ovarian cancer, as well as leukemia. Abeloff had been director of the center's clinical program since 1983.

"The new building will be on campus, but details are still being deliberated," Abeloff says. Along with an increase in needed laboratory space, he says, the new structure will have an enlarged clinical area. The need for more clinical space is a reflection of two factors: the increase of ambulatory patients and a greater number of collaborative programs between the medical departments and other areas of the university, he says.

"One of the major things I want to do as the center's new director," Abeloff says, "is to integrate the activities of the oncology center with the rest ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies